Cargando…

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Detalles Bibliográficos
Autores principales:	Mina, Roberto, Belotti, Angelo, Petrucci, Maria Teresa, Zambello, Renato, Capra, Andrea, Di Lullo, Giacomo, Ronconi, Sonia, Pescosta, Norbert, Grasso, Mariella, Monaco, Federico, Cellini, Claudia, Gobbi, Marco, Ballanti, Stelvio, de Fabritiis, Paolo, Mosca-Siez, Maria Letizia, Marchetti, Monia, Liberati, Anna Marina, Offidani, Massimo, Giuliani, Nicola, Ria, Roberto, Musto, Pellegrino, Romano, Alessandra, Sonneveld, Pieter, Boccadoro, Mario, Larocca, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234990/ https://www.ncbi.nlm.nih.gov/pubmed/32424154 http://dx.doi.org/10.1038/s41408-020-0326-1

Ejemplares similares

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
por: Bringhen, Sara, et al.
Publicado: (2020)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco
por: Dooley, Kelly E, et al.
Publicado: (2011)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

Successful Retreatment With ADOC Chemotherapy in Relapsed Thymic Carcinoma: Experiences in Two Cases
por: Nomura, Yayoi, et al.
Publicado: (2012)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2023)

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation
por: Annemans, Lieven, et al.
Publicado: (2015)

In vitro antifungal susceptibility of yeasts and molds isolated from sputum of tuberculosis relapse and retreatment patients
por: Tonui, Josephat, et al.
Publicado: (2021)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
por: D’agostino, Mattia, et al.
Publicado: (2023)

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
por: Bonello, Francesca, et al.
Publicado: (2019)

Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment
por: Yoo, Su Jin, et al.
Publicado: (2012)

Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
por: Somers, Katherine M., et al.
Publicado: (2023)

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
por: Bonello, Francesca, et al.
Publicado: (2020)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
por: Terpos, Evangelos, et al.
Publicado: (2022)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
por: Montefusco, V., et al.
Publicado: (2023)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
por: Morabito, Fortunato, et al.
Publicado: (2022)

PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
por: Bruzzese, A., et al.
Publicado: (2022)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Cheah, C. Y., et al.
Publicado: (2022)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
por: Mangiacavalli, Silvia, et al.
Publicado: (2022)

Mantle Cell Lymphoma Relapsing at the Lymphedematous Arm
por: Massini, Giuseppina, et al.
Publicado: (2013)

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2020)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

P970: A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
por: Furlan, Anna, et al.
Publicado: (2023)

The influence of 3x3 bonded retainer on anterior crowding relapse in mandibular incisor extraction cases
por: BERBERT, Marcelo, et al.
Publicado: (2021)

P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL
por: Montefusco, Vittorio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vn0os58ipomsqm3fpqn2vp1m3j